Clinical trials: Hepatic Tumors
Liver Cancer
Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
To evaluate the additional efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced liver cancer and treated with tyrosine kinase inhibitors (TKIs) combined with immunotherapy.
- Trial name
- NCT06563934
- Testing
- Oral enterobacterium capsules, Lenvatinib + PD-1 monoclonal antibody
- Volunteers
- 70 people
- Sponsor
- Xu Yong, MD
Liver Cancer
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for liver cancer.
- Trial name
- NCT02447263
- Testing
- interventional therapy
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
This phase Ib trial investigates the side effects of durvalumab and tremelimumab after radioembolization (radiation particles against liver tumors) and to see how well they work in treating patients with liver cancer that cannot…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04605731
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
- Trial name
- TheraSphere (NCT00683631)
- Testing
- TheraSphere HUD
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Louisville
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate
Hepatocellular carcinoma (HCC) is a deadly tumor for which the incidence is increasing in the United States, primarily due to prevalence of hepatitis C infection.
- Trial name
- NCT00006332
- Testing
- Tetrathiomolybdate
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Liver Neoplasms
Liver Cancer Prognosis Investigation Study
This prospective cohort study is designed to explore the role of environmental, clinical, and genetic risk factors in the progression and prognosis of primary liver cancer (PLC).
- Trial name
- NCT06623734
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cancer
The AMARA (As Much As Reasonably Achievable) Study
Subjects with large inoperable liver tumors defined as at least 1 lesion larger than 5cm in maximum diameter. For the purposes of the present study, we define the AMARA principle in intensified regional TARE as a planned…
- Trial name
- NCT06257030
- Testing
- Transarterial Radioembolization
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University Hospital of Patras
Hepatitis C, Cirrhosis
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
The main risk factor for development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual incidence risk between 1-6%; currently the leading cause of death in patients with cirrhosis and the 2nd cause of…
- Conditions
- Hepatitis C, Cirrhosis, Antiviral Drug Adverse Reaction
- Trial name
- NCT03775798
- Testing
- Direct antiviral agents for hepatitis C
- Where
- Argentina
- Volunteers
- 2,200 people
- Sponsor
- Austral University, Argentina
Hepatocellular Carcinoma, Liver Transplant
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current…
- Trial name
- TEP CARE (NCT04792801)
- Testing
- PET TDM FDG-Choline
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Lille
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
Liver Cancer, Hepatobiliary Tract Adenomas and Carcinomas
Observational Study of Biomarker During Liver Surgery
The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver…
- Trial name
- NCT02102971
- Testing
- Hepatocellular carcinoma
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Florida
Lung Cancer, Breast Cancer
Large Language Models Assist in Tumor MDT
Multidisciplinary teams (MDTs) represent the gold standard for personalized tumor treatment, but they are limited by medical resources and accessibility Limitation.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer
- Trial name
- NCT07504367
- Testing
- LLM assists in MDT report writing
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Liver Cancer
To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1…
- Trial name
- NCT05369650
- Testing
- Lidocaine Hydrochloride, Injectable
- Where
- China
- Volunteers
- 120 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma
Recurrence of Hepatocellular Carcinoma
analysis of the risk factors of intra-hepatic distant recurrence (IDR) of hepatocellular carcinoma within 1 year after radiofrequency ablation.
- Trial name
- NCT01520779
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Ain Shams University
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Pancreatic Cancer, Breast Cancer
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
- Conditions
- Pancreatic Cancer, Breast Cancer, Hepatocellular Carcinoma
- Trial name
- NCT05394259
- Testing
- Piflufolastat F18
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center